AHZ Technical Analysis, page-168

Infusion not sold yet - good news because cash in the bank makes ahz less desperate, which should hopefully fetch a better price.

Infusion is currently generating cash, but is a distraction from the main event and is a barrier to consolidating the bulk of operations/management to the US. Better to invest the capital into expanding adapt into China - much larger market - and accelerating TAVR.

Forecasting profitability and a huge sales increase was a blunder, which cost the share price dearly. Dilution has been bad, but we have money in the bank and Star Bright to help us push into China.

Completely understand those that have decided to throw in the towel, but (this time ) I think the share price has definitely bottomed out. Upcoming quarterly should push us higher if US 3D sales prove solid and TGA/EU approval presents further upside opportunity (as does selling infusion at a good price)